CTOs on the Move


 
Amneal (NYSE:AMRX) is building one of the most dynamic pharmaceutical companies in our industry. Today`s healthcare environment requires new ideas. While staying true to our reputation for quality, service and value in pharmaceuticals, we are challenging ourselves, our playbook and the status quo. We are uniting people, passion and products to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow`s health challenges. We are Amneal and “We make healthy possible.” Learn more about how we`re making a difference in generics, brands and biosimilars at Amneal.com.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.amneal.com
  • 400 Crossing Boulevard 3rd Floor
    Bridgewater, NJ USA 08807
  • Phone: 908.947.3120

Executives

Name Title Contact Details
Michelle Santana
Director, Assistant Treasurer Profile
Kevin Crain
Chief Information Security Officer Profile
Vikram Nair
Senior Vice President, Chief Information Officer Profile
Brian Luteran
Director Information Security Profile

Similar Companies

Johnson Matthey Pharmaceutical - West Deptford

Johnson Matthey Pharmaceutical - West Deptford is a Paulsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ridgmar Pharmacy

Ridgmar Pharmacy is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PharmaDerm

PharmaDerm is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Monogram BioSciences

Monogram Biosciences, Inc. (Monogram) is a life sciences company committed to advancing personalized medicine and improving patient outcomes through the development of molecular diagnostic products that guide and target the appropriate treatments

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.